Lake Street initiated coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $4 price target. Bolt has developed next-generation Immune-Stimulating Antibody Conjugates, or ISACs, with optimized conjugation chemistry that have enhanced activity against even lower levels of tumor antigen, the analyst tells investors. Bolt’s lead next-generation ISAC, BDC-4182, has a Phase I clinic trial that is expected to start enrolling patients this quarter and Bolt has deals with Genmab (GMAB) and Toray that fund additional ISACs through early clinical development, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Cautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions
- Cautious Hold Rating on Bolt Biotherapeutics Amid Promising Clinical Data and Financial Uncertainty
- Bolt Biotherapeutics price target lowered to $1 from $1.25 at Stifel
- Bolt Biotherapeutics Reports Q1 2025 Financial Results
- Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)